Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15860395 | 0.83 | KIF11 (0.53) | KIF11DAOKDM1AP2RX7FFAR1 | |
| SCHEMBL2642102 | 0.83 | AR (0.48) | KIF11P2RX7 | |
| SCHEMBL6745234 | 0.83 | RXRA (0.49) | KIF11DAORXRARXRBRXRG | |
| SCHEMBL3637724 | 0.82 | KIF11 (0.51) | KIF11DAOKDM1AP2RX7FFAR1 | |
| SCHEMBL25738425 | 0.80 | KIF11 (0.50) | KIF11DAOKDM1AFFAR1CYP11B1 | |
| SCHEMBL12706035 | 0.79 | KIF11 (0.53) | KIF11DAOKDM1AP2RX7FFAR1 | |
| SCHEMBL19356858 | 0.79 | KIF11 (0.53) | KIF11DAOKDM1AP2RX7FFAR1 | |
| Bromide SCHEMBL582107 | 0.79 | KIF11 (0.53) | KIF11DAOKDM1AP2RX7FFAR1 | |
| SCHEMBL698164 | 0.79 | KIF11 (0.53) | KIF11DAOKDM1AP2RX7FFAR1 | |
| SCHEMBL297408 | 0.79 | KIF11 (0.53) | KIF11DAOKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421847-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-20020022604-A1 | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | PHAMACIA CORPORATION | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022604-A1 | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, F2 | KIF11 4873/4885DAO 691/4885KDM1A 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.